Stockreport

ObsEva Announces Publication of Abstracts from Phase 2b EDELWEISS Trial of Linzagolix in Endometriosis

ObsEva SA - Common Shares  (OBSV) 
Last obseva sa - common shares earnings: 3/5 01:00 am Check Earnings Report
PDF    Significant improvement in quality of life outcomes maintained or increased after 52 weeks of treatment with linzagolixSmall, expected, non-clinically relevant in [Read more]